share_log

Altamira Therapeutics | CORRESP: CORRESP

SEC announcement ·  Jan 18 00:41
Summary by Futu AI
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-3 effective by 5:00 p.m. Eastern Time on January 19, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, as amended, was submitted through a correspondence dated January 17, 2024. The company's legal representative, Alex Dinur of Lowenstein Sandler LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-3 effective by 5:00 p.m. Eastern Time on January 19, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, as amended, was submitted through a correspondence dated January 17, 2024. The company's legal representative, Alex Dinur of Lowenstein Sandler LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.